Clinical trial • Phase IV • Musculoskeletal
Ropivacaine hydrochloride for Hip osteoarthritis | Postoperative pain
Phase IV trial of Ropivacaine hydrochloride for Hip osteoarthritis | Postoperative pain.
Overview
- Trial Therapeutic Area
- Musculoskeletal
- Trial Disease
- Hip osteoarthritis | Postoperative pain
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 03-09-2025
- First CTIS Authorization Date
- 31-10-2025
Trial design
Randomised, comparator arm: bicain spinal (bupivacaine hydrochloride) 5 mg/ml solution for intrathecal use (single-shot intrathecal bupivacaine; max total dose reported 13.5 mg) versus test arm: ropivacain fresenius kabi (ropivacaine hydrochloride) 5 mg/ml solution for intrathecal use (single-shot intrathecal ropivacaine; max total dose reported 16 mg).-controlled Phase IV trial across 1 site in Finland.
- Randomised
- Yes
- Comparator
- Comparator arm: Bicain Spinal (Bupivacaine hydrochloride) 5 mg/ml solution for intrathecal use (single-shot intrathecal bupivacaine; max total dose reported 13.5 mg) versus Test arm: Ropivacain Fresenius Kabi (Ropivacaine hydrochloride) 5 mg/ml solution for intrathecal use (single-shot intrathecal ropivacaine; max total dose reported 16 mg).
- Target Sample Size
- 162
Eligibility
Recruits 162 Vulnerable population not selected. Exclusion criteria include 'Cognitive deficiencies preventing informed consent' and 'Language barrier preventing completion of study form in Finnish'. Informed consent must be understood and signed by participants..
- Pregnancy Exclusion
- Pregnancy or breastfeeding
- Vulnerable Population
- Vulnerable population not selected. Exclusion criteria include 'Cognitive deficiencies preventing informed consent' and 'Language barrier preventing completion of study form in Finnish'. Informed consent must be understood and signed by participants.
Inclusion criteria
- {"criterion_text":"- 18 – 80 years of age\n- Scheduled for a primary elective total hip arthroplasty\n- Patient must be a candidate for same day discharge as determined by local guidelines that will be published separately (incl. ASA 1-2, BMI < 35)\n- Informed consent understood and signed\n- Patient is 160 -186 cm tall"}
Exclusion criteria
- {"criterion_text":"- Scheduled bilateral THA\n- Language barrier preventing completion of study form in Finnish\n- Pregnancy or breastfeeding\n- Chronic pain syndrome\n- Contraindication to or failed spinal anesthesia\n- Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)\n- Diabetes requiring insulin medication\n- Preoperative chronic use of illegal substances\n- Renal insufficiency (eGFR < 60)\n- Unstable psychiatric conditions\n- Severe neurological disorder\n- Cognitive deficiencies preventing informed consent"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Return of sensory and motor function","definition_or_measurement_approach":""}
Secondary endpoints
- {"endpoint_text":"- Post-operative pain evaluated using the Numeric Rating Scale (NRS)","definition_or_measurement_approach":"Measured using the Numeric Rating Scale (NRS)"}
- {"endpoint_text":"- Urinary retention","definition_or_measurement_approach":""}
- {"endpoint_text":"- Post-operative nausea and vomiting","definition_or_measurement_approach":""}
- {"endpoint_text":"- Postoperative opioid consumption in morphine milligram equivalents (MME)","definition_or_measurement_approach":"Measured as opioid consumption converted to morphine milligram equivalents (MME)"}
- {"endpoint_text":"- Patient satisfaction will be evaluated using a 5-point Likert scale","definition_or_measurement_approach":"Measured using a 5-point Likert scale"}
- {"endpoint_text":"- Perioperative hemodynamics","definition_or_measurement_approach":""}
- {"endpoint_text":"- Onset time of block","definition_or_measurement_approach":"Time to onset of sensory/motor block (as stated)"}
- {"endpoint_text":"- Adequacy of anesthesia","definition_or_measurement_approach":""}
- {"endpoint_text":"- Same day discharge rate","definition_or_measurement_approach":"Proportion of patients discharged same day"}
- {"endpoint_text":"- Length of stay in the postoperative care unit and length of hospital stay","definition_or_measurement_approach":"Measured as duration/time in postoperative care unit and total hospital stay"}
Recruitment
- Planned Sample Size
- 162
- Recruitment Window Months
- 13
- Consent Approach
- Informed consent must be understood and signed by the participant. Subject information and consent documents are present (document titles indicate Finnish language availability); exclusion exists for 'Language barrier preventing completion of study form in Finnish.' Participants (aged 18–80) provide consent themselves; no paediatric assent procedures are applicable.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 162
Finland
- Earliest CTIS Part Ii Submission Date
- 19-10-2025
- Latest Decision Or Authorization Date
- 30-04-2026
- Processing Time Days
- 193
- Number Of Sites
- 1
- Number Of Participants
- 162
Sites
- Site Name
- Turku University Hospital
- Department Name
- Anesthesiology and Intensive Care
- Principal Investigator Name
- Panu Uusalo
- Principal Investigator Email
- pijuus@utu.fi
- Contact Person Name
- Panu Uusalo
- Contact Person Email
- pijuus@utu.fi
- Number Of Participants
- 162
Sponsor
Primary sponsor
- Full Name
- Turku University Hospital
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Finland
Third parties
- {"country":"","full_name":"Finnish State Research Funding (VTR) for university level health research.","duties_or_roles":"Source of monetary support","organisation_type":""}
Investigational products
- Investigational Product Name
- Ropivacain Fresenius Kabi 5 mg/ml injektioneste, liuos
- Active Substance
- Ropivacaine hydrochloride
- Modality
- Small molecule
- Routes Of Administration
- Intrathecal
- Route
- Intrathecal
- Authorisation Status
- Authorised (marketing authorisation: 27493)
- Frequency
- Single-shot
- Maximum Dose
- 16 mg
- Investigational Product Name
- Bicain Spinal 5 mg/ml injektioneste, liuos
- Active Substance
- Bupivacaine hydrochloride
- Modality
- Small molecule
- Routes Of Administration
- Intrathecal
- Route
- Intrathecal
- Authorisation Status
- Authorised (marketing authorisation: 12054)
- Frequency
- Single-shot
- Maximum Dose
- 13.5 mg
Related trials
Other published trials that may interest you.